Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
What is the purpose of the top 10 health technology…
Sterile Processing Department (SPD) managers and technicians know a thing…
New York, New York (January 31, 2024)–Sonio today announced that…